Editorial
2002; Wiley; Volume: 22; Issue: 3 Linguagem: Romeno
10.1046/j.0106-9543.2002.00002.x
ISSN1600-0676
AutoresColin A. Sherrington, John K. Olynyk,
Tópico(s)Hepatitis B Virus Studies
ResumoLiverVolume 22, Issue 3 p. 187-189 Editorial C A Sherrington, C A Sherrington 1 Department of Gastroenterology, and 2 The Department of Medicine, University of Western Australia, Fremantle Hospital, Fremantle, Western AustraliaSearch for more papers by this author 1 J K Olynyk, J K Olynyk 1 Department of Gastroenterology, and 2 The Department of Medicine, University of Western Australia, Fremantle Hospital, Fremantle, Western AustraliaSearch for more papers by this author 2 C A Sherrington, C A Sherrington 1 Department of Gastroenterology, and 2 The Department of Medicine, University of Western Australia, Fremantle Hospital, Fremantle, Western AustraliaSearch for more papers by this author 1 J K Olynyk, J K Olynyk 1 Department of Gastroenterology, and 2 The Department of Medicine, University of Western Australia, Fremantle Hospital, Fremantle, Western AustraliaSearch for more papers by this author 2 First published: 05 July 2002 https://doi.org/10.1046/j.0106-9543.2002.00002.xCitations: 11 John Olynyk, University Department of Medicine, Fremantle Hospital, PO Box 480, Fremantle 6959, Western Australia. Tel: 61-8-94313233. Fax: 61-8-94312977. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Di Bisceglie A M, Axiotis C A, Hoofnagle J H, Bacon B R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108– 13. 2 Arber N, Konikoff F M, Moshkowitz M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994; 39: 2656– 9. 3 Bonkovsky H L, Banner B F, Rothman A L. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759– 68. 4 Thorburn D, Curry G, Spooner R, et al. The role of iron and hemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248– 52. 5 Giannini E, Mastracci L, Botta F, et al. Liver iron accumulation in chronic hepatitis C patients without HFE mutations: relationships with histological damage, viral load and genotype and alpha-glutathione S-transferase levels. Eur J Gastroenterol Hepatol 2001; 13: 1355– 61. 6 Casaril M, Stanzial A M, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000; 47: 220– 5. 7 Hezode C, Cazeneuve C, Coue O, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999; 31: 979– 84. 8 Negro F, Samii K, Rubbia-Brandt L, et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000; 60: 21– 7. 9 Jurczyk K, Wawrzynowicz-Syczewska M, Boron-Kaczmarska A, Sych Z. Serum iron parameters in patients with alcoholic and chronic cirrhosis and hepatitis. Med Sci Monit 2001; 7: 962– 5. 10 Fabris C, Toniutto P, Scott C A, et al. Serum iron indices as a measure of iron deposits in chronic hepatitis C. Clin Chim Acta 2001; 304: 49– 55. 11 Chapoutot C, Esslimani M, Joomaye Z, et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 2000; 46: 711– 4. 12 Van Thiel D H, Friedlander L, Fagiuoli S, Wright H I, Irish W, Gavaler J S. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410– 5. 13 Riggio O, Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997; 92: 1298– 301. 14 Olynyk J K, Reddy K R, Di Bisceglie A M, et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104– 9. 15 Olynyk J K, Cullen D J, Aquilia S, Rossi E, Summerville L, Powell L W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718– 24. 16 Bacon B R, Olynyk J K, Brunt E M, Britton R S, Wolff R K. HFE genotype in patients with hemochromatosis and other liver disease. Ann Int Med 1999; 130: 953– 62. 17 Shiono Y, Ikeda R, Hayashi H, et al. C282Y and H63D mutations in the HFE gene have no effect on iron overload disorders in Japan. Intern Med 2001; 40: 852– 6. 18 Hohler T, Leininger S, Kohler H H, Schirmacher P, Galle P R. Heterozygosity for the hemochromatosis gene in liver diseases – prevalence and effects on liver histology. Liver 2000; 20: 482– 6. 19 Lal P, Fernandes H, Koneru B, Albanese E, Hameed M. C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis. Arch Pathol Lab Med 2000; 124: 1632– 5. 20 Pirisi M, Scott C A, Avellini C, et al. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000; 113: 546. 21 Martinelli A L, Franco R F, Villanova M G, et al. Are hemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000; 102: 152– 6. 22 Olynyk J K. Hepatitis C and iron. Keio J Med 1999; 48: 124– 31. 23 Vautier G, Olynyk J K. Porphyria cutanea tarda in the HFE-gene and hepatitis C virus era. Am J Gastroenterol 2000; 95: 3350– 2. 24 Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000; 95: 1041– 50. 25 Kakizaki S, Takagi H, Horiguchi N, et al. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000; 20: 125– 8. 26 Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001; 33: 157– 62. 27 Cagnoni C, Corsini F, Pancotti D, Carrara G. Effect of iron depletion on long-term response to interferon in patients with chronic hepatitis C with increased plasma iron without accumulation of liver iron. Ann Ital Med Int 2000; 15: 132– 8. 28 Bassett S E, Di Bisceglie A M, Bacon B R, et al. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 1999; 29: 1884– 92. 29 Di Bisceglie A M, Bonkovsky H L, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135– 8. 30 Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986– 8. 31 Bacon B R, Rebholz A E, Fried M, Di Bisceglie A M. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C, who failed to respond to interferon-alpha. Hepatology 1993; 18: 150A. 32 Yano M, Hayashi H, Wakusawa S, et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002; 97: 133– 7. 33 Herrera J L. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy. Am J Gastroenterol 1999; 94: 3571– 5. 34 Fong T L, Han S H, Tsai N C, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998; 28: 369– 74. 35 Tsai N C, Zuckerman E, Han S H, Goad K, Redeker A G, Fong T L. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997; 92: 1831– 4. 36 Guyader D, Boucher E, Andre P, et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 1999; 94: 1696– 8. 37 Ortiz V, Olaso V, Lopez Viedma B, et al. The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study. Gastroenterol Hepatol 1999; 22: 122– 6. 38 Fontana R J, Israel J, LeClair P, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000; 31: 730– 6. 39 Fargion S, Ballare M, Belloni G, et al. A multicenter randomized controlled trial in untreated non-cirrhotic patients with chronic hepatitis C. Hepatology 1999; 30: 371A. 40 Sartori M, Andorno S, Rigamonti C, Grossini E, Nicosia G, Boldorini R. Chronic hepatitis C is mild in menstruating women. J Gastroenterol Hepatol 2000; 15: 1411– 7. 41 Bayraktar Y, Koseoglu T, Kayhan B, Uzunalimoglu B, Gurakar A, Van Thiel D H. The use of desferrioxamine infusions to enhance the response rate to interferon alpha (IFN) treatment of chronic viral hepatitis. Gastroenterology 1995; 108 (4 suppl): A1031. 42 Clemente M G, Congia M, Lai M E. Effect of iron overload on the response to recombinant interferon-alpha treatment in transfusion dependent patients with thalassaemia major and chronic hepatitis C. J Pediatr 1994; 125: 123– 8. 43 Di Marco V, Lo Iacono O, Almasio P. Long term efficacy of alpha-interferon treatment in beta-thalassemics with chronic hepatitis C. Blood 1997; 90: 2207– 12. Citing Literature Volume22, Issue3June 2002Pages 187-189 ReferencesRelatedInformation
Referência(s)